Reviewing Moolec Science (MLEC) and Its Competitors

Moolec Science (NASDAQ:MLEC) is one of 495 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Moolec Science to related companies based on the strength of its earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Profitability

This table compares Moolec Science and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Moolec Science	-129.97%	-93.88%	-33.37%
Moolec Science Competitors	-7,261.78%	-105.61%	-28.42%

Institutional & Insider Ownership

0.1% of Moolec Science shares are held by institutional investors. Comparatively, 33.3% of shares of all “Biotechnology” companies are held by institutional investors. 19.9% of Moolec Science shares are held by insiders. Comparatively, 20.3% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and target prices for Moolec Science and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moolec Science	0	0	1	0	3.00
Moolec Science Competitors	981	2826	7076	125	2.58

Moolec Science presently has a consensus price target of $6.00, suggesting a potential upside of 605.88%. As a group, “Biotechnology” companies have a potential upside of 22.50%. Given Moolec Science’s stronger consensus rating and higher probable upside, research analysts clearly believe Moolec Science is more favorable than its competitors.

Earnings and Valuation

This table compares Moolec Science and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Moolec Science	$5.63 million	-$7.31 million	-4.25
Moolec Science Competitors	$213.06 million	-$20.40 million	91.41

Moolec Science’s competitors have higher revenue, but lower earnings than Moolec Science. Moolec Science is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Moolec Science has a beta of -0.54, indicating that its share price is 154% less volatile than the S&P 500. Comparatively, Moolec Science’s competitors have a beta of 1.24, indicating that their average share price is 24% more volatile than the S&P 500.

Summary

Moolec Science competitors beat Moolec Science on 7 of the 13 factors compared.

About Moolec Science

Moolec Science SA, a science-based food ingredient company, focuses on developing real animal proteins in plants using molecular farming. It offers Chymosin SPC, a dairy ingredient; GLA SONOVA, a nutritional oil; POORK+, a plant-based, animal meat free ingredient with porcine proteins in soybeans; and BEEF+, a meat replacement product. It operates in the United States, Europe, and South America. The company was founded in 2020 and is based in Luxembourg.